Fourche J, Texier-Maugein J, Mormede M
Laboratoire de Bactériologie, Hôpital Xavier-Arnozan, Pessac.
Pathol Biol (Paris). 1988 Jun;36(5 Pt 2):665-70.
The authors studied the susceptibility to 5 aminoglycosides (amikacin, dibekacin, gentamicin, netilmicin and tobramycin) of 3,354 strains isolated at the Centre Hospitalier Sud in Bordeaux during 1987. The results are compared to those obtained in 1984 on 2,818 strains. Amikacin remains the most active aminoside against the Enterobacteriaceae and Acinetobacter; against Pseudomonas, tobramycin has become the best one at that time, as well as netilmicin against Staphylococcus aureus. Evolution: no significative increase of Enterobacteriaceae resistance to aminoglycosides was observed during the last 3 years except for Providencia and Serratia. For Acinetobacter and Pseudomonas, percentage of resistant strains is respectively two-fold and three-fold higher. Although resistance increased in that species, netilmicin and amikacin showed a still good activity against Staphylococcus aureus.
作者研究了1987年在波尔多市南部中心医院分离出的3354株菌株对5种氨基糖苷类药物(阿米卡星、地贝卡星、庆大霉素、奈替米星和妥布霉素)的敏感性。将结果与1984年对2818株菌株所获结果进行了比较。阿米卡星仍然是对肠杆菌科细菌和不动杆菌最具活性的氨基糖苷类药物;对于铜绿假单胞菌,妥布霉素当时已成为最佳药物,奈替米星对金黄色葡萄球菌也是如此。演变情况:在过去3年中,除普罗威登斯菌属和沙雷菌属外,未观察到肠杆菌科细菌对氨基糖苷类药物的耐药性有显著增加。对于不动杆菌和铜绿假单胞菌,耐药菌株的百分比分别高出两倍和三倍。尽管该菌种的耐药性有所增加,但奈替米星和阿米卡星对金黄色葡萄球菌仍显示出良好的活性。